Emyria (ASX:EMD) Buyback Yield %: -43.44 (As of Jul. 03, 2026)


What is Emyria Buyback Yield %?

Emyria ASX:EMD +7.89% Buyback Yield % is -43.44 as of Jul. 03, 2026. The stock has 1 warning sign investors should review. Among 272 Healthcare Providers & Services companies, Emyria ranks worse than 93.38% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Emyria's current buyback yield was -43.44%.

Emyria Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Emyria's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Buyback Yield % Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial -16.75 -9.65 -13.44 -29.93 -32.53

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.84 -29.93 -24.43 -32.53 -27.32

ASX:EMD vs VEEV, BTSG, TEM: Buyback Yield % Comparison

For the Health Information Services subindustry, Emyria's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emyria Buyback Yield % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Emyria's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Emyria's Buyback Yield % falls into.


Emyria Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Emyria's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.161 + 5.73) / 17.120628
=-32.53%

Emyria's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.524 + 13.488) / 47.450809
=-27.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -43.44 mean?
Emyria (ASX:EMD) has a Buyback Yield % of -43.44 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Emyria and its competitors. According to the industry distribution chart, Emyria ranks #254 out of 272 companies in the Healthcare Providers & Services industry, placing it in the top 93.4%.
Is Emyria's Buyback Yield % too high?
Emyria's current Buyback Yield % is -43.44. Based on the distribution chart, Emyria ranks #254 out of 272 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Emyria's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #254 out of 272 companies for Buyback Yield %. This places Emyria in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Emyria and its competitors. Emyria's current Buyback Yield % is -43.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 36.7% above its estimated fair value. The current Buyback Yield % is -43.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Buyback Yield % is -43.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.